2023
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Balasubramanian P, Kernan W, Sheth K, Ofstad A, Rosenstock J, Wanner C, Zinman B, Mattheus M, Marx N, Inzucchi S. Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials. Stroke 2023, 54: 2013-2021. PMID: 37449424, PMCID: PMC10358436, DOI: 10.1161/strokeaha.122.042053.Peer-Reviewed Original ResearchConceptsCardiovascular risk factor controlRisk factor controlCoronary artery diseaseEMPA-REG OUTCOMECardiovascular outcome trialsType 2 diabetesRisk factorsOutcome trialsBlood pressureOdds ratioAntiplatelet/anticoagulant medicationsAntiplatelet/anticoagulant therapyDiabetes cardiovascular outcome trialsSuboptimal risk factor controlCardiovascular risk factorsRecurrent ischemic eventsDiastolic blood pressureSystolic blood pressureRespective odds ratiosFactor controlCross-sectional analysisLogistic regression modelsMacrovascular complicationsStatin useAnticoagulant medication
2010
What Is the Future of Stroke Prevention?
Kernan WN, Launer LJ, Goldstein LB. What Is the Future of Stroke Prevention? Stroke 2010, 41: s35-s38. PMID: 20876501, PMCID: PMC4795938, DOI: 10.1161/strokeaha.110.592022.Peer-Reviewed Original ResearchConceptsRisk factorsPolypill approachDrug-related side effectsCardiovascular risk factorsFirst ischemic strokeStroke risk factorsMultiple risk factorsOlder adult populationStroke preventionIschemic strokeBlood pressureCholesterol levelsClinical trialsSide effectsAdult populationPolypillStrokeEntire populationRiskLarge populationPopulationCertain ageMedicationsPharmacodynamicsPharmacokinetics